Isolation, Structure Elucidation and Activity of an Unknown Impurity of Amphotericin B

[1]  Hu Chang-qin,et al.  RP-HPLC determination of amphotericin B and its liposome , 2006 .

[2]  Dai Bi-tao Liposomal amphotericin B for the treatment of 6 fungal pneumonia children with leukemia , 2006 .

[3]  J. Sierra,et al.  Low‐dose amphotericin b lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies – a randomized, controlled trial , 2004, European journal of haematology.

[4]  A. McLachlan,et al.  Amphotericin B in Children with Malignant Disease: a Comparison of the Toxicities and Pharmacokinetics of Amphotericin B Administered in Dextrose versus Lipid Emulsion , 1999, Antimicrobial Agents and Chemotherapy.

[5]  A. Ganser,et al.  Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study , 1998, BMJ.

[6]  L. Frankel,et al.  Treatment of systemic fungal infections with liposomal amphotericin B. , 1989, Archives of internal medicine.

[7]  A. Aszalos,et al.  Quantitation of amphotericins by reverse-phase high-performance liquid chromatography. , 1984, Journal of pharmaceutical sciences.

[8]  P. Sidebottom,et al.  The proton magnetic resonance spectrum of amphotericin B , 1981 .

[9]  S. Feldman,et al.  Toxicity of amphotericin b in children with cancer. , 1979, American journal of diseases of children.

[10]  C. Schaffner,et al.  POLYENE MACROLIDE DERIVATIVES. I , 1972 .

[11]  C. Schaffner,et al.  Structure and absolute configuration of the polyene macrolide antibiotic amphotericin B , 1970 .